APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

New Drug Modeling Solution

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global New Drug Modeling Solution Market Analysis and Forecast 2026-2032

5 July 2026175 pages

Choose your research edition.

Industry ResearchNew Drug Modeling Solution Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal New Drug Modeling Solution Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal New Drug Modeling Solution Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal New Drug Modeling Solution Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal New Drug Modeling Solution Market Analysis and Forecast 2026-2032175 pages · $4,950 USD

Market perspective

The global New Drug Modeling Solution market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for New Drug Modeling Solution is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for New Drug Modeling Solution is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for New Drug Modeling Solution is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for New Drug Modeling Solution is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of New Drug Modeling Solution include JSR Corporation(Crown Bioscience), Chemical Computing Group ULC, Nimbus Therapeutics, schrodinger, Inc, Genedata AG, Biognos AB, Compugen Ltd, Dassault Systemes and Acellera, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for New Drug Modeling Solution, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of New Drug Modeling Solution, also provides the revenue of main regions and countries. Of the upcoming market potential for New Drug Modeling Solution, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the New Drug Modeling Solution revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global New Drug Modeling Solution market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for New Drug Modeling Solution revenue, projected growth trends, production technology, application and end-user industry.

New Drug Modeling Solution Segment by Company

JSR Corporation(Crown Bioscience)

Chemical Computing Group ULC

Nimbus Therapeutics

schrodinger, Inc

Genedata AG

Biognos AB

Compugen Ltd

Dassault Systemes

Acellera

lnstem(Leadscope)

New Drug Modeling Solution Segment by Type

Database

Software

Others

New Drug Modeling Solution Segment by Application

Drug Discovery and Development

Computational Physiological Medicine

Disease Modeling

Others

New Drug Modeling Solution Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global New Drug Modeling Solution market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of New Drug Modeling Solution and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of New Drug Modeling Solution.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of New Drug Modeling Solution in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of New Drug Modeling Solution company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, New Drug Modeling Solution revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global New Drug Modeling Solution Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Database Major Player Table 3. Software Major Player Table 4. Others Major Player Table 5. Global New Drug Modeling Solution Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Drug Discovery and Development Major Player Table 7. Computational Physiological Medicine Major Player Table 8. Disease Modeling Major Player Table 9. Others Major Player Table 10. New Drug Modeling Solution Industry Trends Table 11. New Drug Modeling Solution Industry Drivers Table 12. New Drug Modeling Solution Industry Opportunities and Challenges Table 13. New Drug Modeling Solution Industry Restraints Table 14. Global New Drug Modeling Solution Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global New Drug Modeling Solution Market Size by Region (2021-2026) & (US$ Million) Table 16. Global New Drug Modeling Solution Market Share by Region (2021-2026) Table 17. Global New Drug Modeling Solution Market Size by Region (2027-2032) & (US$ Million) Table 18. Global New Drug Modeling Solution Market Share by Region (2027-2032) Table 19. Global New Drug Modeling Solution Revenue by Players (US$ Million) & (2021-2026) Table 20. Global New Drug Modeling Solution Revenue Market Share by Players (2021-2026) Table 21. Global New Drug Modeling Solution Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global New Drug Modeling Solution Key Players Headquarters & Area Served Table 23. Global New Drug Modeling Solution Players, Product Type & Application Table 24. Global New Drug Modeling Solution Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global New Drug Modeling Solution by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global New Drug Modeling Solution Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global New Drug Modeling Solution Revenue by Type (2021-2026) & (US$ Million) Table 29. Global New Drug Modeling Solution Revenue by Type (2027-2032) & (US$ Million) Table 30. Global New Drug Modeling Solution Revenue Market Share by Type (2021-2026) Table 31. Global New Drug Modeling Solution Revenue Market Share by Type (2027-2032) Table 32. Global New Drug Modeling Solution Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global New Drug Modeling Solution Revenue by Application (2021-2026) & (US$ Million) Table 34. Global New Drug Modeling Solution Revenue by Application (2027-2032) & (US$ Million) Table 35. Global New Drug Modeling Solution Revenue Market Share by Application (2021-2026) Table 36. Global New Drug Modeling Solution Revenue Market Share by Application (2027-2032) Table 37. JSR Corporation(Crown Bioscience) Company Information Table 38. JSR Corporation(Crown Bioscience) Business Overview Table 39. JSR Corporation(Crown Bioscience) New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. JSR Corporation(Crown Bioscience) New Drug Modeling Solution Product Portfolio Table 41. JSR Corporation(Crown Bioscience) Recent Development Table 42. Chemical Computing Group ULC Company Information Table 43. Chemical Computing Group ULC Business Overview Table 44. Chemical Computing Group ULC New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Chemical Computing Group ULC New Drug Modeling Solution Product Portfolio Table 46. Chemical Computing Group ULC Recent Development Table 47. Nimbus Therapeutics Company Information Table 48. Nimbus Therapeutics Business Overview Table 49. Nimbus Therapeutics New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Nimbus Therapeutics New Drug Modeling Solution Product Portfolio Table 51. Nimbus Therapeutics Recent Development Table 52. schrodinger, Inc Company Information Table 53. schrodinger, Inc Business Overview Table 54. schrodinger, Inc New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. schrodinger, Inc New Drug Modeling Solution Product Portfolio Table 56. schrodinger, Inc Recent Development Table 57. Genedata AG Company Information Table 58. Genedata AG Business Overview Table 59. Genedata AG New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Genedata AG New Drug Modeling Solution Product Portfolio Table 61. Genedata AG Recent Development Table 62. Biognos AB Company Information Table 63. Biognos AB Business Overview Table 64. Biognos AB New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Biognos AB New Drug Modeling Solution Product Portfolio Table 66. Biognos AB Recent Development Table 67. Compugen Ltd Company Information Table 68. Compugen Ltd Business Overview Table 69. Compugen Ltd New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Compugen Ltd New Drug Modeling Solution Product Portfolio Table 71. Compugen Ltd Recent Development Table 72. Dassault Systemes Company Information Table 73. Dassault Systemes Business Overview Table 74. Dassault Systemes New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Dassault Systemes New Drug Modeling Solution Product Portfolio Table 76. Dassault Systemes Recent Development Table 77. Acellera Company Information Table 78. Acellera Business Overview Table 79. Acellera New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Acellera New Drug Modeling Solution Product Portfolio Table 81. Acellera Recent Development Table 82. lnstem(Leadscope) Company Information Table 83. lnstem(Leadscope) Business Overview Table 84. lnstem(Leadscope) New Drug Modeling Solution Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. lnstem(Leadscope) New Drug Modeling Solution Product Portfolio Table 86. lnstem(Leadscope) Recent Development Table 87. North America New Drug Modeling Solution Revenue by Type (2021-2026) & (US$ Million) Table 88. North America New Drug Modeling Solution Revenue by Type (2027-2032) & (US$ Million) Table 89. North America New Drug Modeling Solution Revenue by Application (2021-2026) & (US$ Million) Table 90. North America New Drug Modeling Solution Revenue by Application (2027-2032) & (US$ Million) Table 91. North America New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America New Drug Modeling Solution Revenue by Country (2021-2026) & (US$ Million) Table 93. North America New Drug Modeling Solution Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe New Drug Modeling Solution Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe New Drug Modeling Solution Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe New Drug Modeling Solution Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe New Drug Modeling Solution Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe New Drug Modeling Solution Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe New Drug Modeling Solution Revenue by Country (US$ Million) & (2027-2032) Table 101. China New Drug Modeling Solution Revenue by Type (2021-2026) & (US$ Million) Table 102. China New Drug Modeling Solution Revenue by Type (2027-2032) & (US$ Million) Table 103. China New Drug Modeling Solution Revenue by Application (2021-2026) & (US$ Million) Table 104. China New Drug Modeling Solution Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia New Drug Modeling Solution Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia New Drug Modeling Solution Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia New Drug Modeling Solution Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia New Drug Modeling Solution Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia New Drug Modeling Solution Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia New Drug Modeling Solution Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia New Drug Modeling Solution Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA New Drug Modeling Solution Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA New Drug Modeling Solution Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA New Drug Modeling Solution Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA New Drug Modeling Solution Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA New Drug Modeling Solution Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA New Drug Modeling Solution Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. New Drug Modeling Solution Image Figure 2. Global New Drug Modeling Solution Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global New Drug Modeling Solution Market Size Share 2021 VS 2025 VS 2032 Figure 4. Database Image Figure 5. Software Image Figure 6. Others Image Figure 7. Global New Drug Modeling Solution Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global New Drug Modeling Solution Market Size Share 2021 VS 2025 VS 2032 Figure 9. Drug Discovery and Development Image Figure 10. Computational Physiological Medicine Image Figure 11. Disease Modeling Image Figure 12. Others Image Figure 13. Global New Drug Modeling Solution Market Size (US$ Million) & (2021-2032) Figure 14. Global New Drug Modeling Solution Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global New Drug Modeling Solution Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global New Drug Modeling Solution Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global New Drug Modeling Solution Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global New Drug Modeling Solution Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global New Drug Modeling Solution Revenue Market Share by Type (2021-2032) Figure 21. Global New Drug Modeling Solution Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global New Drug Modeling Solution Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global New Drug Modeling Solution Revenue Market Share by Application (2021-2032) Figure 24. North America New Drug Modeling Solution Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America New Drug Modeling Solution Revenue Share by Type (2021-2032) Figure 26. North America New Drug Modeling Solution Revenue Share by Application (2021-2032) Figure 27. North America New Drug Modeling Solution Revenue Share by Country (2021-2032) Figure 28. United States New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe New Drug Modeling Solution Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe New Drug Modeling Solution Revenue Share by Type (2021-2032) Figure 33. Europe New Drug Modeling Solution Revenue Share by Application (2021-2032) Figure 34. Europe New Drug Modeling Solution Revenue Share by Country (2021-2032) Figure 35. Germany New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China New Drug Modeling Solution Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China New Drug Modeling Solution Revenue Share by Type (2021-2032) Figure 45. China New Drug Modeling Solution Revenue Share by Application (2021-2032) Figure 46. Asia New Drug Modeling Solution Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia New Drug Modeling Solution Revenue Share by Type (2021-2032) Figure 48. Asia New Drug Modeling Solution Revenue Share by Application (2021-2032) Figure 49. Asia New Drug Modeling Solution Revenue Share by Region (2021-2032) Figure 50. Japan New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA New Drug Modeling Solution Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA New Drug Modeling Solution Revenue Share by Type (2021-2032) Figure 58. SAMEA New Drug Modeling Solution Revenue Share by Application (2021-2032) Figure 59. SAMEA New Drug Modeling Solution Revenue Share by Country (2021-2032) Figure 60. Brazil New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt New Drug Modeling Solution Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Database
  • Software
  • Others
Applications
  • Drug Discovery and Development
  • Computational Physiological Medicine
  • Disease Modeling
  • Others
Companies covered
  • JSR Corporation(Crown Bioscience)
  • Chemical Computing Group ULC
  • Nimbus Therapeutics
  • schrodinger, Inc
  • Genedata AG
  • Biognos AB
  • Compugen Ltd
  • Dassault Systemes
  • Acellera
  • lnstem(Leadscope)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 New Drug Modeling Solution Market by Type
  3. 1.2.1 Global New Drug Modeling Solution Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Database
  5. 1.2.3 Software
  6. 1.2.4 Others
  7. 1.3 New Drug Modeling Solution Market by Application
  8. 1.3.1 Global New Drug Modeling Solution Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Drug Discovery and Development
  10. 1.3.3 Computational Physiological Medicine
  11. 1.3.4 Disease Modeling
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 New Drug Modeling Solution Market Dynamics
  1. 2.1 New Drug Modeling Solution Industry Trends
  2. 2.2 New Drug Modeling Solution Industry Drivers
  3. 2.3 New Drug Modeling Solution Industry Opportunities and Challenges
  4. 2.4 New Drug Modeling Solution Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global New Drug Modeling Solution Market Perspective (2021-2032)
  2. 3.2 Global New Drug Modeling Solution Growth Trends by Region
  3. 3.2.1 Global New Drug Modeling Solution Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global New Drug Modeling Solution Market Size by Region (2021-2026)
  5. 3.2.3 Global New Drug Modeling Solution Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global New Drug Modeling Solution Revenue by Players
  2. 4.1.1 Global New Drug Modeling Solution Revenue by Players (2021-2026)
  3. 4.1.2 Global New Drug Modeling Solution Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global New Drug Modeling Solution Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global New Drug Modeling Solution Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global New Drug Modeling Solution Key Players Headquarters & Area Served
  7. 4.4 Global New Drug Modeling Solution Players, Product Type & Application
  8. 4.5 Global New Drug Modeling Solution Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global New Drug Modeling Solution Market CR5 and HHI
  11. 4.6.3 2025 New Drug Modeling Solution Tier 1, Tier 2, and Tier 3
5 New Drug Modeling Solution Market Size by Type
  1. 5.1 Global New Drug Modeling Solution Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global New Drug Modeling Solution Revenue by Type (2021-2032)
  3. 5.3 Global New Drug Modeling Solution Revenue Market Share by Type (2021-2032)
6 New Drug Modeling Solution Market Size by Application
  1. 6.1 Global New Drug Modeling Solution Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global New Drug Modeling Solution Revenue by Application (2021-2032)
  3. 6.3 Global New Drug Modeling Solution Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 JSR Corporation(Crown Bioscience)
  2. 7.1.1 JSR Corporation(Crown Bioscience) Company Information
  3. 7.1.2 JSR Corporation(Crown Bioscience) Business Overview
  4. 7.1.3 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  5. 7.1.4 JSR Corporation(Crown Bioscience) New Drug Modeling Solution Product Portfolio
  6. 7.1.5 JSR Corporation(Crown Bioscience) Recent Developments
  7. 7.2 Chemical Computing Group ULC
  8. 7.2.1 Chemical Computing Group ULC Company Information
  9. 7.2.2 Chemical Computing Group ULC Business Overview
  10. 7.2.3 Chemical Computing Group ULC New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Chemical Computing Group ULC New Drug Modeling Solution Product Portfolio
  12. 7.2.5 Chemical Computing Group ULC Recent Developments
  13. 7.3 Nimbus Therapeutics
  14. 7.3.1 Nimbus Therapeutics Company Information
  15. 7.3.2 Nimbus Therapeutics Business Overview
  16. 7.3.3 Nimbus Therapeutics New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Nimbus Therapeutics New Drug Modeling Solution Product Portfolio
  18. 7.3.5 Nimbus Therapeutics Recent Developments
  19. 7.4 schrodinger, Inc
  20. 7.4.1 schrodinger, Inc Company Information
  21. 7.4.2 schrodinger, Inc Business Overview
  22. 7.4.3 schrodinger, Inc New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  23. 7.4.4 schrodinger, Inc New Drug Modeling Solution Product Portfolio
  24. 7.4.5 schrodinger, Inc Recent Developments
  25. 7.5 Genedata AG
  26. 7.5.1 Genedata AG Company Information
  27. 7.5.2 Genedata AG Business Overview
  28. 7.5.3 Genedata AG New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Genedata AG New Drug Modeling Solution Product Portfolio
  30. 7.5.5 Genedata AG Recent Developments
  31. 7.6 Biognos AB
  32. 7.6.1 Biognos AB Company Information
  33. 7.6.2 Biognos AB Business Overview
  34. 7.6.3 Biognos AB New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Biognos AB New Drug Modeling Solution Product Portfolio
  36. 7.6.5 Biognos AB Recent Developments
  37. 7.7 Compugen Ltd
  38. 7.7.1 Compugen Ltd Company Information
  39. 7.7.2 Compugen Ltd Business Overview
  40. 7.7.3 Compugen Ltd New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Compugen Ltd New Drug Modeling Solution Product Portfolio
  42. 7.7.5 Compugen Ltd Recent Developments
  43. 7.8 Dassault Systemes
  44. 7.8.1 Dassault Systemes Company Information
  45. 7.8.2 Dassault Systemes Business Overview
  46. 7.8.3 Dassault Systemes New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Dassault Systemes New Drug Modeling Solution Product Portfolio
  48. 7.8.5 Dassault Systemes Recent Developments
  49. 7.9 Acellera
  50. 7.9.1 Acellera Company Information
  51. 7.9.2 Acellera Business Overview
  52. 7.9.3 Acellera New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Acellera New Drug Modeling Solution Product Portfolio
  54. 7.9.5 Acellera Recent Developments
  55. 7.10 lnstem(Leadscope)
  56. 7.10.1 lnstem(Leadscope) Company Information
  57. 7.10.2 lnstem(Leadscope) Business Overview
  58. 7.10.3 lnstem(Leadscope) New Drug Modeling Solution Revenue and Gross Margin (2021-2026)
  59. 7.10.4 lnstem(Leadscope) New Drug Modeling Solution Product Portfolio
  60. 7.10.5 lnstem(Leadscope) Recent Developments
8 North America
  1. 8.1 North America New Drug Modeling Solution Revenue (2021-2032)
  2. 8.2 North America New Drug Modeling Solution Revenue by Type (2021-2032)
  3. 8.2.1 North America New Drug Modeling Solution Revenue by Type (2021-2026)
  4. 8.2.2 North America New Drug Modeling Solution Revenue by Type (2027-2032)
  5. 8.3 North America New Drug Modeling Solution Revenue Share by Type (2021-2032)
  6. 8.4 North America New Drug Modeling Solution Revenue by Application (2021-2032)
  7. 8.4.1 North America New Drug Modeling Solution Revenue by Application (2021-2026)
  8. 8.4.2 North America New Drug Modeling Solution Revenue by Application (2027-2032)
  9. 8.5 North America New Drug Modeling Solution Revenue Share by Application (2021-2032)
  10. 8.6 North America New Drug Modeling Solution Revenue by Country
  11. 8.6.1 North America New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America New Drug Modeling Solution Revenue by Country (2021-2026)
  13. 8.6.3 North America New Drug Modeling Solution Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe New Drug Modeling Solution Revenue (2021-2032)
  2. 9.2 Europe New Drug Modeling Solution Revenue by Type (2021-2032)
  3. 9.2.1 Europe New Drug Modeling Solution Revenue by Type (2021-2026)
  4. 9.2.2 Europe New Drug Modeling Solution Revenue by Type (2027-2032)
  5. 9.3 Europe New Drug Modeling Solution Revenue Share by Type (2021-2032)
  6. 9.4 Europe New Drug Modeling Solution Revenue by Application (2021-2032)
  7. 9.4.1 Europe New Drug Modeling Solution Revenue by Application (2021-2026)
  8. 9.4.2 Europe New Drug Modeling Solution Revenue by Application (2027-2032)
  9. 9.5 Europe New Drug Modeling Solution Revenue Share by Application (2021-2032)
  10. 9.6 Europe New Drug Modeling Solution Revenue by Country
  11. 9.6.1 Europe New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe New Drug Modeling Solution Revenue by Country (2021-2026)
  13. 9.6.3 Europe New Drug Modeling Solution Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China New Drug Modeling Solution Revenue (2021-2032)
  2. 10.2 China New Drug Modeling Solution Revenue by Type (2021-2032)
  3. 10.2.1 China New Drug Modeling Solution Revenue by Type (2021-2026)
  4. 10.2.2 China New Drug Modeling Solution Revenue by Type (2027-2032)
  5. 10.3 China New Drug Modeling Solution Revenue Share by Type (2021-2032)
  6. 10.4 China New Drug Modeling Solution Revenue by Application (2021-2032)
  7. 10.4.1 China New Drug Modeling Solution Revenue by Application (2021-2026)
  8. 10.4.2 China New Drug Modeling Solution Revenue by Application (2027-2032)
  9. 10.5 China New Drug Modeling Solution Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia New Drug Modeling Solution Revenue (2021-2032)
  2. 11.2 Asia New Drug Modeling Solution Revenue by Type (2021-2032)
  3. 11.2.1 Asia New Drug Modeling Solution Revenue by Type (2021-2026)
  4. 11.2.2 Asia New Drug Modeling Solution Revenue by Type (2027-2032)
  5. 11.3 Asia New Drug Modeling Solution Revenue Share by Type (2021-2032)
  6. 11.4 Asia New Drug Modeling Solution Revenue by Application (2021-2032)
  7. 11.4.1 Asia New Drug Modeling Solution Revenue by Application (2021-2026)
  8. 11.4.2 Asia New Drug Modeling Solution Revenue by Application (2027-2032)
  9. 11.5 Asia New Drug Modeling Solution Revenue Share by Application (2021-2032)
  10. 11.6 Asia New Drug Modeling Solution Revenue by Country
  11. 11.6.1 Asia New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia New Drug Modeling Solution Revenue by Country (2021-2026)
  13. 11.6.3 Asia New Drug Modeling Solution Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA New Drug Modeling Solution Revenue (2021-2032)
  2. 12.2 SAMEA New Drug Modeling Solution Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA New Drug Modeling Solution Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA New Drug Modeling Solution Revenue by Type (2027-2032)
  5. 12.3 SAMEA New Drug Modeling Solution Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA New Drug Modeling Solution Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA New Drug Modeling Solution Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA New Drug Modeling Solution Revenue by Application (2027-2032)
  9. 12.5 SAMEA New Drug Modeling Solution Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA New Drug Modeling Solution Revenue by Country
  11. 12.6.1 SAMEA New Drug Modeling Solution Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA New Drug Modeling Solution Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA New Drug Modeling Solution Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst